Clinical and economic outcomes of myasthenia gravis and myasthenic crisis when treated with PLEX and IVIG
Although PLEX has been advocated as first-line therapy due to rapid clinical improvement, national data do not clearly indicate a superior treatment option, with similar mortality and total charges observed across therapies.
Authors
- Eli Blaney (ORCID: https://orcid.org/0000-0001-9956-2510)
- Tamara Diehl
- Mohsin Mirza (ORCID: https://orcid.org/0000-0001-8399-7368)
- Abubakar Tauseef (ORCID: https://orcid.org/0000-0002-4317-1868)
- Ali Bin Abdul Jabbar (ORCID: https://orcid.org/0000-0001-5145-8626)
- Makenzie Maroney
- Saif Zurob
Institutions
- Creighton University (US)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fneur.2025.1713388
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Creighton University